Nowicky Pharma (FZE)
P.O. Box 48748,
United Arab Emirates
Inventor and patent owner
Dr. Wassil Nowicky
Margaretenstr. 7, A-1040 Vienna, Austria
Tel.: (+43 1) 586 12 23 Fax: (+43 1) 586 89 94
|EFFECT of UKRAIN ON PROSTATIC CANCER|
74 patients with prostatic carcinoma were involved in a controlled study at the Villa Medica Clinic (Edenkoben, Germany). These patients had already been treated according to all conventional therapy protocols, and due to relapse and/or progression of the disease had no further conventional options available. They were treated with UKRAIN, and partially at the same time with local hyperthermia, and the following results were obtained: complete remission in 73% of patients and partial remission in 22%, with only 5% of patients showing no effect on the progress of the disease ( 144, 192).
Depending on the general condition of the patient and the extent of the tumour, the best dosage of UKRAIN proved to be a stable one of 5, 10, 15 or 20 mg per injection daily or every second or third day. The toxins which are created by the regression of larger tumours can cause a poisoning of the whole body and worsen the general condition; this limits the application of UKRAIN at higher doses. In small doses, it was found that UKRAIN brings about improvement in the immune system. Higher doses bring about tumour regression ( 17).